.svg){kind=small}
Discover Opportunities months before the RFP drops
Learn more →Discover Opportunities months before the RFP drops
Learn more →The IV&V partner will be a commercial entity that will support the government’s Program Management Team to assess the performing teams’ progress, as required by the government. This commercial entity must be technically, managerially, and financially independent of all developmental performing teams. An IV&V partner will ensure reproducibility and credibility of data generated by Performers at critical assessment points throughout the program. Additionally, IV&V will supply government-selected cell types to Performers to be used for technology demonstrations. Proposers selected to receive funding related to research and development under TA1 or TA2 are not eligible to work as an IV&V partner. See attached file.
Posted Date
Dec 2, 2025
Due Date
Mar 26, 2026
Release: Dec 2, 2025
Close: Mar 26, 2026
The IV&V partner will be a commercial entity that will support the government’s Program Management Team to assess the performing teams’ progress, as required by the government. This commercial entity must be technically, managerially, and financially independent of all developmental performing teams. An IV&V partner will ensure reproducibility and credibility of data generated by Performers at critical assessment points throughout the program. Additionally, IV&V will supply government-selected cell types to Performers to be used for technology demonstrations. Proposers selected to receive funding related to research and development under TA1 or TA2 are not eligible to work as an IV&V partner. See attached file.
AvailableEvidence-Based Validation & Innovation for Rapid Therapeutics in Behavioral Health (EVIDENT) imitative as a method to efficiently fund innovative solutions in support of HHS and ARPA-H objectives.
Posted Date
Nov 24, 2025
Due Date
Dec 5, 2025
Release: Nov 24, 2025
Close: Dec 5, 2025
Evidence-Based Validation & Innovation for Rapid Therapeutics in Behavioral Health (EVIDENT) imitative as a method to efficiently fund innovative solutions in support of HHS and ARPA-H objectives.
The contractor must provide independent validation & verification (iv&v) support services for the react program which requires the contractor to (1) characterize production of unmodified pancreatic cells to establish an approach to produce differentiated cells; (2) characterize production of react performer cells; (3) validate performance characteristics of performer living pharmacy therapeutic production and living sentinel biomarker sensing; and (4) prepare technical reports for the government with analytical characterization of performer cells and/or validation of performance and recommendations on how performer teams can optimize cell differentiation protocols to align with fda requirements.
Posted Date
Nov 24, 2025
Due Date
Jan 5, 2026
Release: Nov 24, 2025
Close: Jan 5, 2026
The contractor must provide independent validation & verification (iv&v) support services for the react program which requires the contractor to (1) characterize production of unmodified pancreatic cells to establish an approach to produce differentiated cells; (2) characterize production of react performer cells; (3) validate performance characteristics of performer living pharmacy therapeutic production and living sentinel biomarker sensing; and (4) prepare technical reports for the government with analytical characterization of performer cells and/or validation of performance and recommendations on how performer teams can optimize cell differentiation protocols to align with fda requirements.
AvailableMore RFPs available with Premium →
Get alerted before the bid drops, know which RFPs to pursue, and generate compliant drafts with AI.
Premium
Access the largest public sector contact database
Premium
Get complete source documentation & analysis